Biomedical Learning Institute

	Taught by the Experts
Please Note: The Oncology Learning Center has changed its name to Biomedical Learning Institute
Home Faculty Library Live CME Courses In Development On-Demand CME Cutaneous Malignancies Managing Melanoma Patients NSCLC Maintenance Therapy Breast Cancer Lung, Head & Neck Cancer Hematology Contact Us Contact Us About Us Scientific Advisory Board Capability Presentation Archives

Overview

Disclosure

Agenda

Hotel Accommodations

Registration

Symposium Co-Chairs

Dennis Slamon MD PhD
Dennis J. Slamon, MD, PhD
Chief, Division of Hematology-Oncology
Professor and Executive Vice Chair, Department of Medicine
Director for Clinical Research, Jonsson Comprehensive Cancer Center
Director, Revlon/UCLA Women's Health Research
and Cancer Research Programs
University of California at Los Angeles School of Medicine
Los Angeles, California

Lisa Carey MD
Lisa A. Carey, MD
Medical Director
UNC Breast Center
University of North Carolina
Lineberger Comprehensive Cancer Center
Chapel Hill, NC

Expert Faculty

Kathy S Albain MD
Kathy S. Albain, MD
Professor of Medicine, Hematology/Oncology
Cardinal Bernardin Cancer Center
Loyola University Health Center
Maywood, IL

Harold J Burstein MD PhD
Harold J. Burstein, MD, PhD
Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, MA

Matthew G Ewend MD
Matthew G. Ewend, MD
Department Chair
Professor of Neurosurgery
University of North Carolina
Lineberger Comprehensive Cancer Center
Chapel Hill, NC

Julie R Gralow MD
Julie R. Gralow, MD
Professor of Medical Oncology
Cancer Care Alliance
University of Washington School of Medicine
Seattle, WA

Clifford A Hudis MD
Clifford A. Hudis, MD
Chief, Breast Cancer Medicine Service
Memorial Sloan-Kettering Cancer Center
New York, NY

Monica Morrow MD
Monica Morrow, MD
Chief, Breast Service
Department of Surgery
Anne Burnett Windfohr Chair of Clinical Oncology
Memorial Sloan-Kettering Cancer Center
New York, NY

Hyman B Muss MD
Hyman B. Muss, MD
Professor of Medicine and Oncology
Director, Geriatric Oncology Program
University of North Carolina
Lineberger Comprehensive Cancer Center
Chapel Hill, NC

C Kent Osborne MD
C. Kent Osborne, MD
Director, Breast Center at Baylor College of Medicine
Director, Baylor Cancer Center
Professor of Medicine and Cellular and Structural Biology
Baylor Cancer Center
Houston, TX

Mark Pegram MD
Mark Pegram, MD
Professor of Medicine and Oncology
Director, Breast Cancer Program
University of Miami Cancer Center
Miami, FL

Edith A Perez MD
Edith A. Perez, MD
Group Vice Chair, Alliance for Clinical Trials in Oncology
Deputy Director,
Mayo Clinic Cancer Center
Serene M. and Frances C. Durling Professor of Medicine
Mayo Clinic
Jacksonville, FL

Andrea L Richardson MD PhD
Andrea L. Richardson, MD, PhD
Assistant Professor
Department of Pathology
Harvard Medical School
Active Staff and Associate Physician
Surgical Pathology
Brigham And Women�s Hospital
Boston, MA

Hope Rugo MD
Hope Rugo, MD
Clinical Professor
Department of Hematology/Oncology
Director, Breast Oncology Clinical Trials Program
UCSF Helen Diller Comprehensive Cancer Center
San Francisco, CA

Eric P Winer MD
Eric P. Winer, MD
Director, Breast Oncology Center
Thompson Investigator in Breast Cancer Research
Department of Medical Oncology
Dana-Farber Cancer Institute
Harvard Cancer Center
Boston, MA

Fifth Annual Symposium on Personalized Therapies and
Best Clinical Practices for Breast Cancer

CASE-BASED LEARNING

Click here for the agenda

The Peabody Orlando

February 25, 2012 - Orlando, FL

Personalized medicine for treating breast cancer is a reality. This past year there has been much new "practice-changing" data published that affects the optimal way to treat, manage and care for your patients with breast cancer. This symposium will help you improve your selection of the most appropriate new therapeutic strategies, and will also help you to identify the patient sub-populations of breast cancer who will respond to personalized therapies.

Taught by the top academic experts and best teachers, this is THE symposium on breast cancer that you should attend in 2012. It also provides the most relevant data from the December 2011 San Antonio Breast Cancer Symposium. This is the fifth year of this symposium and it continues to attract a full room of breast cancer clinicians who leave the program with the expert knowledge and competence needed to improve patient outcomes.


•	Overview
•	Educational Statement of Need
•	Disclosure
•	Target Audience
•	Learning Objectives
•	CME Credit Information
•	Agenda
•	The Peabody Orlando
•	Registration
•	Exhibit

Agenda

Saturday, February 25, 2012
6:30AM - 8:00AM	Breakfast
6:30AM	Registration

Introduction

8:00AM	Welcome, Introductions and CME Pre Test	Lisa Carey
8:10AM	Keynote lecture Dr. Dennis Slamon: Personalized therapy for breast cancer 2012, including an update on adjuvant therapy	Dennis Slamon

Session 1: HER2-Positive Breast Cancer: Factors Impacting Patient Management Decisions – HER2 Biology and Testing Updates – CHAIR: Harold Burstein

8:30AM	What constitutes a HER2-positive tumor? Biology of HER2-positive disease What are the clinically important subtypes?	Mark Pegram
8:40AM	What are the optimal HER2 molecular tests? On which patients are they most beneficial? New HER2 Molecular Testing Strategies FISH, IHC and other established HER2 tests With which therapies do HER2 tests help?	Andrea Richardson
9:00AM	Treatment of Adjuvant and Neoadjuvant HER2-Positive Breast Cancer: Interactive Patient Case Studies How do we treat lower-risk tumors? What is the optimal duration of therapy? Is neoadjuvant anti-HER2 strategy ready for "prime time?" Is one approach emerging as being more effective? Are two-drug combinations more effective than single anti-HER2? What trials are available today? What non-HER2-directed therapies should be considered	Mark Pegram
9:20AM	Treatment of HER2-positive metastatic breast cancer: Interactive Patient Case Studies What are the most effective options for initial and refractory patients? Is one approach emerging as being more effective? Are two-drug combinations more effective than single anti-HER2? How do we select the optimal strategies for these patients? Can we improve upon anti-HER2 strategies? What new options (HER2-directed and non-HER2-targeted) will be available soon?	Edith Perez
9:40AM	Interactive Expert Roundtable Panel Discussion and Audience Q & A Are therapy doublets a new standard of care for HER2-positive patients? What is the new paradigm for managing initial and refractory patients?	Session #1 Faculty
10:00AM	BREAK

Session 2: ER-Positive Breast Cancer - Rethinking the Management of ER-Positive Disease Across All Lines of Therapy - Chair: Kent Osborne

10:30AM	Should ER be the Primary Target for ER-Positive Breast Cancer?	Kent Osborne
10:40AM	Treatment of adjuvant and neoadjuvant ER-positive breast cancer: Interactive Patient Case Studies For which patients is neoadjuvant anti-endocrine therapy appropriate? What is the optimal management systemic strategy for higher-risk patients with low to intermediate recurrence scores? What are the optimal molecular tests for helping guide therapy and patient management? When should chemotherapy be a component of systemic therapy? When should anti-endocrine and anti-HER2 strategies be combined?	Kathy Albain
11:00AM	Treatment of metastatic ER-positive breast cancer: Interactive Patient Case Studies Should the traditional role of anti-estrogens be re-examined? Are response rates higher and reached more quickly with chemotherapy or is this the result of our patient selection? For which patients should chemotherapy be added to endocrine therapy, e.g., symptomatic versus asymptomatic? How should a patient with ER-positive, infiltrating lobular breast cancer be managed upon first recurrence following adjuvant therapy? When should high-dose anti-endocrine therapy be used in the first-line metastatic setting? What are the optimal strategies for second-line therapy? What new agents appear promising?	Hyman Muss
11:20AM	Interactive Expert Roundtable Panel Discussion and Audience Q & A	Session #2 Faculty & Audience
12:00PM	LUNCH WITH THE PROFESSORS

Session 3: Triple-Negative Breast Cancer: Rethinking the Management of Triple-Negative Disease Across All Lines of Therapy – CHAIR: Lisa Carey

1:00PM	What progress have we made? What is the near-term outlook for more improvement? Which of the numerous systemic therapies appear the most promising? What molecular testing should be done for these patients? Which patients should be tested? What is the update on the role of anti-angiogenesis?	Lisa Carey
1:10PM	Management of Triple-Negative Breast Cancer in the adjuvant and neoadjuvant settings: Interactive Patient Case Studies Are strategies using anti-angiogenesis plus chemotherapy appropriate for certain subtypes of patients with triple-negative breast cancer? How do dose-dense and novel strategies compare?	Eric Winer
1:30PM	Point-CounterPoint Debate: What is the optimal systemic strategy for targeting the microtubule for triple-negative metastatic breast cancer? novel taxanes and traditional taxanes (Hyman Muss) epothilone analogues (Hope Rugo) microtubule dynamics inhibitors (Harold Burstein)	Hyman Muss Hope Rugo Harold Burstein
2:10PM	Treatment of metastatic Triple-Negative Breast Cancer: Interactive Patient Case Studies Is PFS a reasonable endpoint for efficacy for patients with metastatic breast cancer? For triple-negative breast cancer is anti-angiogenesis an option along with chemotherapy as a patient management strategy? How can we personalize therapy based upon patient characteristics? Is tolerability to systemic therapy a valid characteristic for treatment personalization?	Hope Rugo
2:30PM	Interactive Expert Roundtable Panel Discussion and Audience Q & A	Session #3 Faculty
2:45PM	BREAK

Session 4: Novel Agents and Special Breast Cancer Patient Populations – CHAIR: Clifford Hudis

3:00PM	Managing the elderly patient with breast cancer: Interactive Patient Case Studies Assessing elderly patients for systemic therapy eligibility How can we predict therapy-induced toxicity? What systemic strategies and clinical tools are available for the clinician for managing elderly patients with breast cancer? What special issues should be considered before breast cancer systemic therapy is determined?	Hyman Muss
3:20PM	The optimal management of bone disease in patients with breast cancer RANK Ligand Inhibition Bisphosphonates New and emerging strategies	Julie Gralow
3:40PM	Inhibiting novel targets and pathways involved in breast cancer therapy: Interactive Patient Case Studies mTOR in both neoadjuvant and metastatic settings kinase and multiple kinase inhibition Other novel targets and pathways	Eric Winer
4:00PM	Personalizing local-regional breast cancer therapies – How have we advanced our strategies to improve outcomes in the clinic? Interactive Patient Case Studies	Monica Morrow
4:20PM	Issues and challenges regarding multidisciplinary management of brain metastasis in breast cancer: Interactive patient case studies	Matthew Ewend
4:40PM	Interactive Expert Roundtable Panel Discussion and Audience Q & A	Session #4 Faculty & Audience
4:55PM	CME/CE posttest and comparisons of pre-test and post-test answers	Dennis Slamon
5:00PM	ADJOURN

Educational Grants

Sincere appreciation is extended to the following companies for their generous commercial support of this educational meeting:

1415 Legacy Drive, Suite 250 • Frisco, TX 75034 • Registration Phone: 214.269.2014 • Fax: 214.866.0311
Contact Us

Disclaimer: The material published on the Biomedical Learning Institute(BLI) Web site reflects the opinions and expertise of the authors and/or reviewers of the material, and not the opinions of the BLI, the CME provider, or the commercial supporters providing educational grants. The materials may address uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. Before using any therapeutic approaches reviewed in this material, a qualified physician should be consulted. Readers of this content should verify all information and data before treating patients or using any drugs or therapies described in any BLI materials. Click here for our Privacy Policy.